Trials / Completed
CompletedNCT07064720
Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine with Mannitol | receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol |
| DRUG | Mannitol (20%) | receive 0.5 g/kg of mannitol |
Timeline
- Start date
- 2024-07-12
- Primary completion
- 2025-12-22
- Completion
- 2026-01-15
- First posted
- 2025-07-15
- Last updated
- 2026-01-21
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07064720. Inclusion in this directory is not an endorsement.